Forge Therapeutics
2 known investors
Find your way into Forge Therapeutics
Forge Therapeutics operates a drug discovery platform focused on developing medicines that target human metalloenzymes. The company works on a pipeline of therapeutic programs based on this metalloenzyme-targeting approach.
Investors · 2
Non-dilutive funding · 1 SBIR/STTR award
Federal grants — no equity taken| Agency | Phase | Year | Amount |
|---|---|---|---|
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2016 | $150K |
Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.
In the news
Frequently asked questions
- What does Forge Therapeutics do?
- Forge Therapeutics operates a drug discovery platform focused on developing medicines that target human metalloenzymes. The company works on a pipeline of therapeutic programs based on this metalloenzyme-targeting approach.
- Who are Forge Therapeutics's investors?
- Forge Therapeutics's investors include MC Healthcare Ventures, Alexandria.